Washington Hospital
Welcome,         Profile    Billing    Logout  
 9 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gutman, Robert E
NCT03520114: Retropubic vs. Single-Incision Mid-Urethral Sling for Stress Urinary Incontinence

Completed
N/A
280
US
RP sling placement, SIS placement
Wake Forest University Health Sciences, Foundation for Female Health Awareness
Stress Urinary Incontinence, Pelvic Floor Disorders
01/24
01/24
POMEGRANATE, NCT06634459: Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment

Recruiting
N/A
182
US
Reia System, Standard of Care Pessary
Medstar Health Research Institute
Pelvic Organ Prolapse, Prolapse
10/25
10/26
APPROVE, NCT06797245: Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

Recruiting
N/A
596
US
RiSolve App, AUGS Patient Handouts
Medstar Health Research Institute, Foundation for Female Health Awareness (FFHA)
Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia, Urinary Frequency
07/26
07/28
Lynce, Filipa
NCT01796197: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Active, not recruiting
2
23
US
Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
Dana-Farber Cancer Institute
Breast Cancer
06/18
11/24
NCT02623972: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Active, not recruiting
2
22
US
Eribulin, Halaven, B1939 mesylate, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan®, Neosar®
Dana-Farber Cancer Institute, Eisai Inc.
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
05/21
12/26
NCT02876302: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Active, not recruiting
2
23
US
Ruxolitinib, Jakafi, Paclitaxel, Taxol, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan
Dana-Farber Cancer Institute, Incyte Corporation
Inflammatory Breast Cancer (IBC)
12/22
12/24
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TRUDI, NCT05795101: TDXD+Durva in HER2+/low IBC

Recruiting
2
63
NA
Trastuzumab deruxtecan, Enhertu, Durvalumab
Filipa Lynce, MD, AstraZeneca, Daiichi Sankyo, Inc.
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
12/27
12/32
EDO-S101-1002, NCT03345485 / 2020-004246-11: Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Completed
1/2
71
Europe, Canada, US
Tinostamustine 60mg/m2 over 30min, EDO-S101, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, EDO-S101., Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Mundipharma Research Limited, Mundipharma Research Limited
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
ZAP-IT, NCT06351332: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC

Recruiting
1/2
78
US
Azenosertib, ZN-c3, KP-2638, Carboplatin, C6H12N2O4Pt, platinum, diammine[1,1-cyclobutanedicarboxylato(2-)- O,O']-, (SP-4-2), Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1-mAB (H409A11) IgG4, C6504H10004N1716O2036S46
Filipa Lynce, MD, Merck Sharp & Dohme LLC, Zentalis Pharmaceuticals
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
03/27
09/29
NCT03641755: Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Active, not recruiting
1
10
US
Sapacitabine, CYC682, Olaparib, Lynparza
Dana-Farber Cancer Institute, AstraZeneca, Cyclacel Pharmaceuticals, Inc.
Breast Cancer
04/22
06/25
NCT06488378: Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Recruiting
1
20
NA
Axatilimab, SNDX-6352, Ab969.g2, C24H23FN4O3, Olaparib, Lynparza, AZD2281, KU-005943
Dana-Farber Cancer Institute, Incyte Corporation
Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
09/26
03/29
Novielli, Nellie
WI223281, NCT03535506: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

Terminated
2
17
US
Palbociclib, Ibrance
Georgetown University, Pfizer
DCIS
12/23
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
Peterson, Joanna L
NCT00001405: Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

Recruiting
N/A
850
US
National Institute of Allergy and Infectious Diseases (NIAID)
Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked, Genetic Disease, Inborn
 
 

Download Options